Marcus Jewell Sells 12,562 Shares of Cellebrite DI (NASDAQ:CLBT) Stock

Cellebrite DI Ltd. (NASDAQ:CLBT) CRO Marcus Jewell sold 12,562 shares of Cellebrite DI stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $11.24, for a total value of $141,196.88. Following the transaction, the executive owned 427,128 shares of the company’s stock, valued at $4,800,918.72. This represents a 2.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Marcus Jewell also recently made the following trade(s):

• On Wednesday, August 12th, Marcus Jewell sold 411 shares of Cellebrite DI stock. The shares were sold at an average price of $16.07, for a total value of $6,604.77.

Cellebrite DI Price Performance

Shares of Cellebrite DI stock opened at $11.29 on Wednesday. The business has a fifty day simple moving average of $14.21 and a two-hundred day simple moving average of $13.81. Cellebrite DI Ltd. has a 1 year low of $9.58 and a 1 year high of $19.98. The company has a market capitalization of $2.82 billion, a price-to-earnings ratio of 51.32, a P/E/G ratio of 1.59 and a beta of 1.18.

Wall Street Analysts Forecast Growth

Several analysts recently commented on CLBT shares. Needham & Company LLC reduced their target price on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating for the company in a report on Friday, August 14th. JPMorgan Chase & Co. reduced their price objective on Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating for the company in a report on Friday, August 14th. Lake Street Capital decreased their target price on Cellebrite DI from $21.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. DA Davidson lowered their target price on Cellebrite DI from $22.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. Finally, Weiss Ratings cut Cellebrite DI from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, August 13th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $16.70.

Trending Headlines about Cellebrite DI

Here are the key news stories impacting Cellebrite DI this week:

• Positive Sentiment: Analyst sentiment remains broadly constructive: five analysts maintain Buy ratings, and the consensus price target is $16.70. Lake Street, DA Davidson, JPMorgan and Needham all retained positive ratings despite lowering their targets. Analyst ratings and price targets
• Positive Sentiment: Institutional ownership remains substantial at approximately 45.9%, with several funds—including Principal Financial, Renaissance Technologies and Roubaix Capital—reporting increased positions. This may provide some underlying support for the stock. Institutional ownership data
• Neutral Sentiment: The reported short-interest data shows zero shares sold short and a zero-day short-interest ratio. Because the figures imply no measurable short position and include an anomalous percentage change, they offer little useful signal for CLBT’s near-term direction.
• Negative Sentiment: Cellebrite’s chief marketing officer, David Nicholas Gee, sold an additional 4,323 shares worth about $49,100 on August 24, following a sale of 2,198 shares worth approximately $24,700 on August 21. The transactions reduced his holdings by 3.1% and 1.55%, respectively. The latest sale was conducted under a pre-arranged Rule 10b5-1 plan, which reduces—but does not eliminate—the bearish interpretation. CMO insider sale filing
• Negative Sentiment: The chief revenue officer, Marcus Jewell, sold 12,562 shares for approximately $141,200 on August 21. Multiple executive sales in a short period can pressure sentiment, particularly while the stock is well below its 52-week high. CRO insider sale filing
• Negative Sentiment: Kaplan Fox and Block & Leviton announced investigations into potential securities-law violations involving Cellebrite. The announcements do not establish wrongdoing, but they introduce legal and reputational risk and are likely contributing to selling pressure. Kaplan Fox investigation announcement

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. California State Teachers Retirement System increased its holdings in shares of Cellebrite DI by 1,595.2% during the second quarter. California State Teachers Retirement System now owns 1,972,752 shares of the company’s stock worth $28,802,000 after purchasing an additional 1,856,378 shares during the period. Wellington Management Group LLP boosted its stake in shares of Cellebrite DI by 93.7% in the second quarter. Wellington Management Group LLP now owns 3,049,904 shares of the company’s stock valued at $44,529,000 after buying an additional 1,475,579 shares during the period. Public Employees Retirement System of Ohio acquired a new stake in Cellebrite DI during the second quarter worth approximately $454,000. Elevation Wealth Partners LLC bought a new position in Cellebrite DI during the 2nd quarter worth $44,000. Finally, Moody National Bank Trust Division raised its holdings in Cellebrite DI by 7.6% in the 2nd quarter. Moody National Bank Trust Division now owns 60,691 shares of the company’s stock valued at $886,000 after acquiring an additional 4,284 shares in the last quarter. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.